The Top 5 Biosimilar Articles for the Week of July 21

Here are the top 5 biosimilar articles for the week of July 21, 2025.

Number 5: Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the Biologics Price Competition and Innovation Act (BPCIA) without needing Congressional approval.

Number 4: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.

Number 3: Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates.

Number 2: Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

Number 1: The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

To read all of these articles and more, visit centerforbiosimilars.com.